Introduction: Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia due to impaired insulin secretion or action. The global prevalence of DM is increasing rapidly, threatening public health and quality of life. In Mongolia, the incidence of type 2 diabetes mellitus (T2DM) has shown a continuous upward trend, highlighting the need for effective plant-derived formulations with glucose-lowering potential.
This study aimed to evaluate the antihyperglycemic effect of composite formulations containing Lagerstroemia speciosa L. (Banaba), Helianthus tuberosus L., and Dasiphora fruticosa L. in alloxan-induced diabetic rats. Methods: T2DM was induced in Wistar rats by intraperitoneal injection of alloxan monohydrate (170 mg/kg). The rats were divided into seven groups: Group 1: healthy control, Group 2: diabetic control, Group 7: metformin-treated (40 mg/200 g), and four treatment groups (Groups 3-6) receiving different combinations of Banaba, Jerusalem artichoke, and Shrubby cinquefoil extracts for 19 consecutive days. Blood glucose levels were measured daily using a GluNeo® Lite glucometer.
After 19 days, animals in Group and Group 6 exhibited significant reductions in blood glucose levels compared with the diabetic (Group 2) and metformin-treated (Group 7) controls (p<0.01). Group 5 demonstrated the greatest hypoglycemic effect, reducing glucose levels by 43.4% relative to the diabetic control group (Group 2). Conclusion Composite formulations containing Banaba, Helianthus tuberosus L., and Dasiphora fruticosa L. exhibited significant antihyperglycemic activity in alloxan-induced diabetic rats. The formulation with Banaba (24 mg) + Helianthus tuberosus L. (200 mg) + Dasiphora fruticosa L. (100 mg) showed the most potent glucose-lowering effect, comparable to metformin, indicating its potential as a promising herbal formulation for T2DM management.

Introduction: Doxylamine succinate has an anticholinergic effect and is an antihistaminic active compound. Drugs containing this active compound relieve the symptoms of allergies, allergic rhinitis, and the common cold and treat short-term insomnia.
In Mongolia’s National Drug Registration list, five doxylamine succinate-based tablets are cataloged, and imported from France, Turkey, Slovenia, India, and South Korea. Doxylamine succinate tablets have not yet been introduced into production within domestic industries. Therefore, we have developed tablets featuring novel technology and standardization. Purpose: This study aims to investigate the research on technology and standardization of doxylamine succinate tablets and assess the viability of their introduction into domestic manufacturing. Methods: For the technological study, the main raw material was purchased from Apollo Healthcare Ltd. in China, and tablets of 5 versions were obtained by wet granulation compression method. Carr’s index and Hausner’s ratio of the granules were calculated according to the British pharmacopeia.
For the standardization study, we purchased standards from Sigmaaldrich® and determined physical, and chemical parameters by Mongolian National Pharmacopoeia (MNP) and United States Pharmacopoeia (USP). Results: Version 2’s Carr’s index was 8.15%, and Hausner’s ratio was 1.09, indicating that the tablet’s compressibility and flowability of granules are excellent. Moreover, version 3’s Carr’s index was 10.70%, and Hausner’s ratio was 1.12, which indicates the tablet’s compressibility and flowability of granules are good.
Both versions above met the requirements as appearance, friability, breaking force, weight variation limits, dissolution, and assay according to USP and MNP. Despite that, only version 3 conformed to disintegration for requirements outlined in the MNP. Conclusion The assay determination method has been validated following ICH guidelines and the quality attributes of the tablet have been specified. Based on the results obtained, version 3 of the experimental tablets is deemed feasible for introduction into production.